MX2015011430A - Antagonismo de la miostatina en seres humanos. - Google Patents

Antagonismo de la miostatina en seres humanos.

Info

Publication number
MX2015011430A
MX2015011430A MX2015011430A MX2015011430A MX2015011430A MX 2015011430 A MX2015011430 A MX 2015011430A MX 2015011430 A MX2015011430 A MX 2015011430A MX 2015011430 A MX2015011430 A MX 2015011430A MX 2015011430 A MX2015011430 A MX 2015011430A
Authority
MX
Mexico
Prior art keywords
human subjects
myostatin
peptibody
antagonism
myostatin antagonist
Prior art date
Application number
MX2015011430A
Other languages
English (en)
Inventor
Ian Desmond Padhi
Huiquan Han
Christopher Michael Haqq
Isaac Ciechanover
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015011430A publication Critical patent/MX2015011430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)

Abstract

Se describen aquí los métodos para tratar o modular la caquexia y/o aumento de la masa corporal magra y/o mejorar el tamaño muscular de las extremidades inferiores en un paciente con cáncer de próstata; dichos métodos comprenden administrar una cantidad terapéuticamente eficaz de un antagonista de la miostatina.
MX2015011430A 2013-03-15 2014-03-14 Antagonismo de la miostatina en seres humanos. MX2015011430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799928P 2013-03-15 2013-03-15
PCT/US2014/029502 WO2014144903A1 (en) 2013-03-15 2014-03-14 Myostatin antagonism in human subjects

Publications (1)

Publication Number Publication Date
MX2015011430A true MX2015011430A (es) 2016-04-20

Family

ID=51537829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011430A MX2015011430A (es) 2013-03-15 2014-03-14 Antagonismo de la miostatina en seres humanos.

Country Status (15)

Country Link
US (1) US20160038588A1 (es)
EP (1) EP2968463A4 (es)
JP (1) JP2016516064A (es)
KR (1) KR20150140294A (es)
CN (1) CN105530949A (es)
AU (1) AU2014228423A1 (es)
CA (1) CA2906835A1 (es)
CL (1) CL2015002691A1 (es)
EA (1) EA201591825A1 (es)
HK (1) HK1220367A1 (es)
IL (1) IL241437A0 (es)
MX (1) MX2015011430A (es)
PH (1) PH12015502155A1 (es)
SG (1) SG11201507413XA (es)
WO (1) WO2014144903A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP3366692A1 (en) 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2014236769B2 (en) * 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3274523B1 (en) 2015-03-23 2019-11-13 Aqua Products Inc. Self-propelled robotic swimming pool cleaner with power-wash assembly for lifting debris from a surface beneath the pool cleaner
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN112292144A (zh) 2018-01-12 2021-01-29 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3569614A1 (en) * 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5017116B2 (ja) * 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド 修飾Ｆｃ分子
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI454479B (zh) * 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
AU2010301196A1 (en) * 2009-10-01 2012-05-17 Myostin Therapeutics Pty Ltd Synthetic myostatin peptide antagonists
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients

Also Published As

Publication number Publication date
WO2014144903A1 (en) 2014-09-18
HK1220367A1 (zh) 2017-05-05
KR20150140294A (ko) 2015-12-15
US20160038588A1 (en) 2016-02-11
JP2016516064A (ja) 2016-06-02
EP2968463A1 (en) 2016-01-20
EA201591825A1 (ru) 2016-05-31
EP2968463A4 (en) 2016-11-23
IL241437A0 (en) 2015-11-30
CL2015002691A1 (es) 2016-04-29
CA2906835A1 (en) 2014-09-18
AU2014228423A1 (en) 2015-11-05
PH12015502155A1 (en) 2016-01-25
CN105530949A (zh) 2016-04-27
SG11201507413XA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
PH12015502155A1 (en) Myostatin antagonism in human subjects
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
MX340290B (es) Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
IL233557A0 (en) Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed
TW201613578A (en) Pharmaceutical combinations
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017011937A (es) Antagonistas del receptor de nk-3 para el tratamiento terapeutico o cosmetico de la grasa corporal excesiva.
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
PH12017500392A1 (en) Medical treatments based on anamorelin
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
EP3015111A4 (en) Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018000287A (es) Dispositivo de electroestimulacion.
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
RU2014119669A (ru) Способ блокады подлопаточной мышцы